Zentalis Pharmaceuticals Inc (ZNTL) Stock Price, Quote & News

Company Profile

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its product candidates include ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, for the treatment of advanced solid tumors and hematological malignancies. It is in a Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; a Phase 2 clinical trial in Cyclin E1-driven hig...

Industry: Biotechnology

Sector: Healthcare

Phone: 212 433 3791

Website: zentalis.com

Address:

1359 Broadway, Suite 1710, New York, United States

Snackdaddy Jun. 27 at 8:42 PM

$ZNTL 8mil dump. another big sell off. jumped all over the 1.18-1.20

1 · Reply

Snackdaddy Jun. 27 at 7:37 PM

$ZNTL nibble here back in at 1.19-1.20

0 · Reply

NNTrader Jun. 27 at 6:43 PM

$ZNTL added some

0 · Reply

LabPsycho Jun. 20 at 5:43 PM

$ZNTL I would be interested in MS history with this stock...pushing buy recommendations when it was 20, 30 or 40? then unloading at the bottom?

0 · Reply

Gaben Jun. 14 at 8:23 PM

$ZNTL Morgan Stanley sells all its shares. This is certainly not new news for many. But it does say a lot.

0 · Reply

Winning_calls Jun. 10 at 2:18 PM

$ZNTL let's 👊👊👊

0 · Reply

Winning_calls Jun. 9 at 3:41 AM

$ZNTL pick me up @ $1.51

0 · Reply

RunnerSignals Jun. 4 at 8:26 PM

Gap Down, Glory Up $AGMH $ASST $ZNTL $WULF $CIFR came out swinging red at the open, green by the bell! That's how market warriors do it.

0 · Reply

Sillyspuh Jun. 4 at 3:27 PM

$ZNTL Really nice bump after the Jeffries conference today. I listened in and Igmar did a great job answering some pointed questions. Gave more context to why this stock has tanked so much in last few years, and why it is positioned to rise now.

0 · Reply

NNTrader Jun. 4 at 3:13 PM

$ZNTL good move

0 · Reply

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 14, 2025, 4:05 PM EDT - 6 weeks ago

Zentalis Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Progress

May 1, 2025, 5:00 PM EDT - 2 months ago

Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Apr 28, 2025, 8:00 AM EDT - 2 months ago

Zentalis Pharmaceuticals Announces First Patient Dosed in DENALI Part 2 Clinical Trial of Azenosertib in Patients with Cyclin E1+ PROC

Apr 23, 2025, 4:05 PM EDT - 2 months ago

Zentalis Pharmaceuticals Announces Poster Presentation at 2025 ASCO Annual Meeting

Mar 26, 2025, 4:05 PM EDT - 3 months ago

Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates

Mar 25, 2025, 4:40 PM EDT - 3 months ago

Zentalis Pharmaceuticals to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025

Mar 15, 2025, 11:25 AM EDT - 3 months ago

Zentalis Pharmaceuticals Presents Updated Clinical Data at the Society of Gynecologic Oncology 2025 Annual Meeting on Women's Cancer

Mar 3, 2025, 8:00 AM EST - 4 months ago

Zentalis Pharmaceuticals Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women's Cancer

Feb 24, 2025, 4:05 PM EST - 4 months ago

Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences

Jan 29, 2025, 7:00 AM EST - 5 months ago

Zentalis Pharmaceuticals Shares Updated Clinical Data Demonstrating Meaningful Azenosertib Activity in Cyclin E1+, Platinum-Resistant Ovarian Cancer

Jan 28, 2025, 4:05 PM EST - 5 months ago

Zentalis Pharmaceuticals Announces Strategic Restructuring to Support Late-Stage Azenosertib Development

Jan 9, 2025, 7:00 AM EST - 6 months ago

Zentalis Pharmaceuticals Announces Azenosertib Fast Track Designation and Virtual Corporate Event to Present Updated Data from Azenosertib Clinical Studies

Dec 12, 2024, 7:00 AM EST - 7 months ago

Zentalis Pharmaceuticals Announces Key Management Appointments

Nov 21, 2024, 1:14 PM EST - 7 months ago

Kuehn Law Encourages Investors of Zentalis Pharmaceuticals, Inc. to Contact Law Firm

Oct 7, 2024, 2:03 PM EDT - 9 months ago

FMR LLC Adjusts Its Stake in Zentalis Pharmaceuticals Inc

Sep 16, 2024, 9:00 AM EDT - 10 months ago

FDA Removes Partial Hold On Zentalis Pharmaceuticals' Azenosertib Studies In Patients With Gynecological Cancers

Sep 16, 2024, 7:00 AM EDT - 10 months ago

Zentalis Pharmaceuticals Announces FDA Has Lifted Partial Clinical Hold on Azenosertib Studies

Sep 9, 2024, 7:00 AM EDT - 10 months ago

Zentalis Pharmaceuticals to Present Preclinical Azenosertib Data at ESMO 2024

Aug 19, 2024, 4:55 PM EDT - 11 months ago

Newman Ferrara LLP Announces Corporate Governance Investigation of Zentalis Pharmaceuticals, Inc. – ZNTL

Aug 19, 2024, 11:00 AM EDT - 11 months ago

Investors In Zentalis Pharmaceuticals Inc Encouraged To Participate In Fraud Investigation With The Schall Law Firm

Aug 18, 2024, 11:00 AM EDT - 11 months ago

Shareholders With Losses In Zentalis Pharmaceuticals Inc Invited To Join Fraud Investigation With Schall Law Firm

Aug 17, 2024, 11:00 AM EDT - 11 months ago

Zentalis Pharmaceuticals Inc Investors Asked To Partake In Fraud Investigation With Schall Law Firm

Aug 16, 2024, 11:00 AM EDT - 11 months ago

Zentalis Pharmaceuticals Inc Stockholders Invited To Join In Fraud Investigation With Schall Law Firm

Aug 15, 2024, 4:00 PM EDT - 11 months ago

Zentalis Pharmaceuticals, Inc. (ZNTL) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Aug 15, 2024, 11:00 AM EDT - 11 months ago

Zentalis Pharmaceuticals Inc Investors Welcome To Join Fraud Investigation With Schall Law Firm

Aug 14, 2024, 10:30 PM EDT - 11 months ago

Zentalis Pharmaceuticals Inc Shareholders Invited To Join Fraud Investigation With Schall Law Firm

Aug 14, 2024, 1:00 AM EDT - 11 months ago

Zentalis Pharmaceuticals Inc Investors Welcome To Participate In Fraud Investigation With Schall Law Firm

Aug 12, 2024, 11:15 PM EDT - 11 months ago

Zentalis Pharmaceuticals Inc Investors Invited To Join Fraud Investigation With Schall Law Firm

Aug 9, 2024, 9:15 PM EDT - 11 months ago

Zentalis Pharmaceuticals Inc Investors Can Participate In Fraud Investigation With The Schall Law Firm

Snackdaddy Jun. 27 at 8:42 PM

$ZNTL 8mil dump. another big sell off. jumped all over the 1.18-1.20

1 · Reply

Snackdaddy Jun. 27 at 7:37 PM

$ZNTL nibble here back in at 1.19-1.20

0 · Reply

NNTrader Jun. 27 at 6:43 PM

$ZNTL added some

0 · Reply

LabPsycho Jun. 20 at 5:43 PM

$ZNTL I would be interested in MS history with this stock...pushing buy recommendations when it was 20, 30 or 40? then unloading at the bottom?

0 · Reply

Gaben Jun. 14 at 8:23 PM

$ZNTL Morgan Stanley sells all its shares. This is certainly not new news for many. But it does say a lot.

0 · Reply

Winning_calls Jun. 10 at 2:18 PM

$ZNTL let's 👊👊👊

0 · Reply

Winning_calls Jun. 9 at 3:41 AM

$ZNTL pick me up @ $1.51

0 · Reply

RunnerSignals Jun. 4 at 8:26 PM

Gap Down, Glory Up $AGMH $ASST $ZNTL $WULF $CIFR came out swinging red at the open, green by the bell! That's how market warriors do it.

0 · Reply

Sillyspuh Jun. 4 at 3:27 PM

0 · Reply

NNTrader Jun. 4 at 3:13 PM

$ZNTL good move

0 · Reply

gilheydari Jun. 3 at 10:06 PM

$ZNTL

0 · Reply

Sillyspuh Jun. 2 at 8:55 PM

$ZNTL https://www.investing.com/news/analyst-ratings/hc-wainwright-maintains-buy-rating-on-zentalis-stock-after-asco-update-93CH-4075448

0 · Reply

G101SPM Jun. 2 at 11:17 AM

$ZNTL $1.17 ask. BUY/ADD 4X to long position on improved SPM tag to EXIT. DAC (dollar average cost includes this BUY) (8) $2.28. EXIT $7.00 (long term).

0 · Reply

gilheydari May. 27 at 7:13 PM

$ZNTL any idea why he has 9.9% (https://en.wikipedia.org/wiki/Billy_Walters_(gambler))

1 · Reply

justiceforb_85 May. 21 at 4:08 AM

$ZNTL are there any catalysts for azenosertib this year?

1 · Reply

JarvisFlow May. 15 at 2:52 PM

Wedbush has adjusted their stance on Zentalis Pharma ( $ZNTL ), setting the rating to Neutral with a target price of 4.

0 · Reply

JarvisFlow May. 15 at 12:00 PM

HC Wainwright & Co. has updated their rating for Zentalis Pharma ( $ZNTL ) to Buy with a price target of 10.

0 · Reply

DonCorleone77 May. 14 at 8:29 PM

$ZNTL Zentalis reports Q1 EPS (67c), consensus (61c) "We continued advancement of azenosertib and made solid progress against our strategic goals in the first quarter. The initiation of DENALI Part 2 moves us into a new chapter as a late-stage development company focusing on a significant patient population in platinum-resistant ovarian cancer with limited choices," said Julie Eastland, Chief Executive Officer of Zentalis. "Our team remains focused on the enrollment and execution of DENALI. Zentalis is financially and organizationally well-positioned to continue advancing azenosertib as a potential treatment option for PROC patients."

0 · Reply

Armonica423 May. 11 at 12:24 AM

$ZNTL Big exposure for CYDY at 3 oncology conferences this coming week, do your dd research

0 · Reply

Massimo21 May. 1 at 1:59 PM

$ZNTL Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) has reported that Director Scott Myers acquired 21,000 shares of the company’s common stock on April 30, 2025. The shares were purchased at an average price of $1.3987 per share, resulting in a total transaction value of $29,372. Following this acquisition, Myers now holds 281,192 shares directly. https://www.investing.com/news/insider-trading-news/zentalis-pharmaceuticals-director-scott-myers-acquires-29372-in-stock-93CH-4014869

0 · Reply

Sillyspuh Apr. 29 at 1:09 AM

$ZNTL Summaries of 4 recent posters presented at AACR: https://ir.zentalis.com/node/10556/html#a994jamesonetal_azenoenc.htm

0 · Reply

Snackdaddy Apr. 28 at 2:18 PM

$ZNTL no push off this news?

0 · Reply

Market Cap	84.90M
Revenue (ttm)	67.43M
Net Income (ttm)	-165.84M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-245.94%
Debt to Equity Ratio	0.00

Volume	8,828,000
Avg Vol	982,784
Day's Range	N/A - N/A
Shares Out	71.95M
Stochastic %K	5%
Beta	1.61
Analysts	Sell
Price Target	$5.86